Attached files
| file | filename |
|---|---|
| 8-K - BODY OF FORM 8-K - Teligent, Inc. | d79598_igi8k.htm |
Exhibit 99.1
News From
![[ex99_79598004.gif]](ex99_79598004.gif)
Release Date: August 13, 2012
Contact:
Jenniffer Collins
IGI Laboratories, Inc.
(856) 697-1441
www.igilabs.com
IGI LABORATORIES ANNOUNCES 2nd QUARTER 2012 RESULTS
BUENA, NJ - (BUSINESS WIRE) – IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the second quarter ended June 30, 2012.
Second Quarter 2012 Highlights vs. 2011
•
Total revenues of $2.4 million for Q2 2012, an increase of 20% over same quarter in 2011
•
Total year to date revenues of $4.3 million, an increase of 19% over the same period in 2011
•
In Q2 2012, IGI submitted three additional abbreviated new drug applications (ANDAs) to the US FDA, bringing the company’s total number of submissions to eight
•
Gross margins improved to 31% in Q2 2012 as compared to 25% in Q1 2012, and were unchanged from Q2 2011
•
Gross margins year to date improved to 29% in 2012 as compared to 27% in 2011
•
Net loss was reduced by $0.4 million to $0.6 million in Q2 2012 as compared to $1.0 million in the same quarter in 2011
•
Net loss per share was $0.01 per share in the second quarter of 2012 as compared to $0.02 in 2011
•
Net loss included research and development costs of $0.6 million and $0.8 million in 2012 and 2011
•
IGI announced the appointment of Jason Grenfell-Gardner as President and CEO
IGI’s President and Chief Executive Officer, Jason Grenfell-Gardner, stated, “IGI completed its second quarter with total revenues of $2.4 million, which is a record quarter for IGI. IGI’s total cash used in operations was $0.9 million, therefore, excluding our $1.1 million of research and development costs year to date to develop our own portfolio of products, our contract formulation and manufacturing services business generated $0.2 million in cash. IGI’s continued improvement in our financial results and successful submission of three ANDAs in the second quarter is certainly a testament to the strong team in place at IGI and I look forward to working with the team to continue to execute on our business plan, to be a leading developer and manufacturer of generic topical prescription drug products.”
IGI will hold a conference call at 4:30 pm ET on Monday, August 13, 2012 to discuss 2nd quarter 2012 results. The Company invites you to listen to the call by dialing 1-866-825-3209. International participants should call 1-617-213-8061. The passcode for the conference call is 24988661. This call is being webcast by Thomson and can be accessed at IGI's website at www.igilabs.com.
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
For the three months ended June 30, 2012 and 2011 and
the six months ended June 30, 2012 and 2011
(in thousands, except share and per share information)
(Unaudited)
|
| Three months ended June 30, |
| Six months ended June 30, | ||||
|
| 2012 |
| 2011 |
| 2012 |
| 2011 |
Revenues: |
|
|
|
|
|
|
|
|
Product sales |
| $ 1,861 |
| $ 1,724 |
| $ 3,371 |
| $ 3,085 |
Research and development income |
| 564 |
| 268 |
| 872 |
| 420 |
Licensing, royalty and other income |
| 12 |
| 32 |
| 26 |
| 93 |
Total revenues |
| 2,437 |
| 2,024 |
| 4,269 |
| 3,598 |
|
|
|
|
|
|
|
|
|
Cost and expenses: |
|
|
|
|
|
|
|
|
Cost of sales |
| 1,683 |
| 1,393 |
| 3,049 |
| 2,634 |
Selling, general and administrative expenses |
| 615 |
| 758 |
| 1,273 |
| 1,691 |
Product development and research expenses |
| 644 |
| 752 |
| 1,116 |
| 1,131 |
Total costs and expenses |
| 2,942 |
| 2,903 |
| 5,438 |
| 5,456 |
Operating loss |
| (505) |
| (879) |
| (1,169) |
| (1,858) |
Interest expense and other, net |
| (83) |
| (68) |
| (154) |
| (122) |
|
|
|
|
|
|
|
|
|
Net loss |
| $ (588) |
| $ (947) |
| $(1,323) |
| $(1,980) |
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share |
| $ (0.01) |
| $ (0.02) |
| $ (0.03) |
| $ (0.05) |
|
|
|
|
|
|
|
|
|
Weighted Average of Common Stock and |
|
|
|
|
|
|
|
|
Basic and diluted |
| 39,522,868 |
| 39,482,968 |
| 39,511,745 |
| 39,398,497 |
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the six months ended June 30, 2012 and 2011
(in thousands)
|
| 2012 |
|
| 2011 |
Cash flows from operating activities: |
|
|
|
|
|
Net loss |
| $(1,323) |
|
| $(1,980) |
Non-cash expenses |
| 539 |
|
| 562 |
Changes in operating assets and liabilities |
| (147) |
|
| (791) |
|
|
|
|
|
|
Net cash used in operating activities |
| (931) |
|
| (2,209) |
|
|
|
|
|
|
Net cash used in investing activities |
| (336) |
|
| (78) |
|
|
|
|
|
|
Net cash provided by financing activities |
| 4 |
|
| 558 |
|
|
|
|
|
|
Net decrease in cash and cash equivalents |
| (1,263) |
|
| (1,729) |
Cash and cash equivalents at beginning of period |
| 2,914 |
|
| 5,116 |
Cash and cash equivalents at end of period |
| $ 1,651 |
|
| $ 3,387 |
IGI LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share information)
| June 30, |
| December 31, | ||
ASSETS |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
| $ 1,651 |
|
| $ 2,914 |
Accounts receivable, less allowance for doubtful accounts of $16 as of June 30, 2012 |
| 1,579 |
|
| 1,208 |
Inventories |
| 1,246 |
|
| 1,195 |
Other receivables |
| 9 |
|
| 239 |
Prepaid expenses |
| 181 |
|
| 130 |
Total current assets |
| 4,666 |
|
| 5,686 |
|
|
|
|
|
|
Property, plant and equipment, net |
| 2,863 |
|
| 2,800 |
Restricted cash, long term |
| 54 |
|
| 54 |
License fee, net |
| 350 |
|
| 400 |
Debt issuance costs, net |
| 558 |
|
| 639 |
Other |
| 180 |
|
| 57 |
Total assets |
| $ 8,671 |
|
| $ 9,636 |
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
| $ 740 |
|
| $ 629 |
Accrued expenses |
| 658 |
|
| 611 |
Deferred income, current |
| 39 |
|
| 38 |
Capital lease obligation, current |
| 37 |
|
| 38 |
Total current liabilities |
| 1,474 |
|
| 1,316 |
|
|
|
|
|
|
Note payable, related party |
| 500 |
|
| 500 |
Deferred income, long term |
| 22 |
|
| 25 |
Capital lease obligation, long term |
| 43 |
|
| 30 |
Total liabilities |
| 2,039 |
|
| 1,871 |
|
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity: |
| 500 |
|
| 500 |
Series C Convertible Preferred stock, liquidation preference - $1,725,171 at |
| 1,517 |
|
| 1,517 |
Common stock |
| 415 |
|
| 415 |
Additional paid-in capital |
| 46,436 |
|
| 46,246 |
Accumulated deficit |
| (40,841) |
|
| (39,518) |
Less treasury stock, 1,965,740 common shares at cost |
| (1,395) |
|
| (1,395) |
Total stockholders’ equity |
| 6,632 |
|
| 7,765 |
Total liabilities and stockholders' equity |
| $ 8,671 |
|
| $ 9,636 |
About IGI Laboratories, Inc.
IGI Laboratories is focused in the development and commercialization of products for the dermatology market.
IGI Laboratories, Inc. “Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. This press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as " will," "possible," "one time," "provides an opportunity," "continue" or words of similar meaning. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption "Risk Factors" in IGI Laboratories, Inc.’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Actual results may differ materially from these expectations due to changes in global political, economic, business, competitive, market and regulatory factors or IGI Laboratories, Inc.’s ability to implement business strategies. IGI Laboratories, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.